Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

BACKGROUND: In PALOMA-2, palbociclib–letrozole significantly improved progression-free survival (PFS) vs placebo–letrozole in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) in the first-line setting. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Hirofumi, Shimizu, Chikako, Masuda, Norikazu, Ohtani, Shoichiro, Ohno, Shinji, Takahashi, Masato, Yamamoto, Yutaka, Nishimura, Reiki, Sato, Nobuaki, Ohsumi, Shozo, Iwata, Hiroji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Lu, Dongrui R., Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399183/
https://www.ncbi.nlm.nih.gov/pubmed/30515674
http://dx.doi.org/10.1007/s10147-018-1353-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399183/
https://www.ncbi.nlm.nih.gov/pubmed/30515674
http://dx.doi.org/10.1007/s10147-018-1353-9

Ejemplares similares